



## Curriculum Vitae

Personal information **Omar Ahmed Awad Awad**

### Work experience

---

- Employer: Paul Ehrlich Institute
  - Start date: 04.2026
  - End date: Present
  - Position: Scientific officer - Regulatory Principles, Innovation Office
  - Employer: Paul Ehrlich Institute
  - Country: Germany
  - Activities:
- Employer: Paul Ehrlich Institute
  - Start date: 04.2020
  - End date: 03.2026
  - Position: PhD candidate
  - Country: Germany
  - Activities: Microbiology and antibiotics research
- Employer: Baheya Hospital
  - Start date: 05.2018
  - End date: 10.2018
  - Position: Clinical pharmacist
  - Country: Egypt
  - Activities: Preparation of individualized chemotherapy, ensuring absence of drug interactions, and monitoring treatment outcomes
- Employer: Marina Pharmacy
  - Start date: 02.2018
  - End date: 04.2018
  - Position: Pharmacist
  - Country: Egypt
  - Activities:

### Education and training

---

- Goethe University Frankfurt
  - Start date: 04.2020
  - End date: Present
  - Qualification: PhD in Pharmacy (expected at the end of this year)
  - Country: Germany
  - Skills: Microbiology and antibiotics research
- Chamber of pharmacists Hessen (LAK)
  - Start date: 07.2023
  - End date: 07.2023
  - Qualification: Technical language skills based on level C1 for practicing the profession of pharmacist
  - Country: Germany
  - Skills:
- Goethe University Frankfurt
  - Start date: 10.2018
  - End date: 02.2020
  - Qualification: Master of science in Pharmacy
  - Skills: Research
- Cairo University
  - Start date: 10.2011
  - End date: 05-2016
  - Qualification: Bachelor of pharmacy (clinical pharmacy)
  - Skills:

### Additional information

---

#### Publications

- Brat C, Huynh Phuoc HP, **Awad O**, Parmar BS, Hellmuth N, Heinicke U, Amr S, Grimmer J, Sürün D, Husnjak K, Carlsson M, Fahrer J, Bauer T, Krieg SC, Manolikakes G, Zacharowski K, Steinhilber D, Münch C, Maier TJ, Roos J. Endogenous anti-tumorigenic nitro-fatty acids inhibit the ubiquitin-proteasome system by directly targeting the 26S proteasome. *Cell Chem Biol.* 2023 Oct 19;30(10):1277-1294.e12. doi: 10.1016/j.chembiol.2023.06.017. Epub 2023 Jul 19. PMID: 37473760.
- Fischer D, Thies F, **Awad O**, Brat C, Meybohm P, Baer PC, Müller MM, Urbschat A, Maier TJ, Zacharowski K, Roos J. Red Blood Cell-Derived Microparticles Exert No Cancer Promoting Effects on Colorectal Cancer Cells In Vitro. *Int J Mol Sci.* 2022 Aug 18;23(16):9323. doi: 10.3390/ijms23169323. PMID: 36012587; PMCID: PMC9409112.
- Hellmuth N, Brat C, **Awad O**, George S, Kahnt A, Bauer T, Huynh Phuoc HP, Steinhilber D, Angioni C, Hassan M, Hock KJ, Manolikakes G, Zacharowski K, Roos J, Maier TJ. Structural Modifications Yield Novel Insights Into the Intriguing Pharmacodynamic Potential of Anti-inflammatory Nitro-Fatty Acids. *Front Pharmacol.* 2021 Nov 18;12:715076. doi: 10.3389/fphar.2021.715076. PMID: 34867322; PMCID: PMC8637440.

- Piesche M, Roos J, Kühn B, Fettel J, Hellmuth N, Brat C, Maucher IV, **Awad O**, Matrone C, Comerma Steffensen SG, Manolikakes G, Heinicke U, Zacharowski KD, Steinhilber D, Maier TJ. The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer. *Front Pharmacol.* 2020 Sep 3;11:1297. doi: 10.3389/fphar.2020.01297. PMID: 33013366; PMCID: PMC7495092.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)